MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze TEM →
    • FindStock Picks / Stock Screener
    • Value · TEMIntrinsic Value Calculator
    • Invest · TEMInvestment Case
    • Hold · TEM5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
TEM stock logo

TEM

Tempus AI, Inc.

$69.77
1.45
 (2.12%)
Exchange:  NASDAQ
Market Cap:  12.237B
Shares Outstanding:  160.708M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Medical – Healthcare Information ServicesView industry performance
   
CEO:  Eric Lefkofsky
Full Time Employees:  3800
Address: 
600 West Chicago Avenue
Chicago
IL
60654
US
Website:  https://www.tempus.com
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician’s desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

Click to read more…

Revenue Segmentation

MarketSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
TETEM logoTEMTempus AI, Inc.12.2B——-13.9%
BTBTSG logoBTSGBrightSpring Health Services, Inc. Com…12.4B44.634.48.9%
HNHNGE logoHNGEHinge Health, Inc.8.5B76.445.426.3%
HQHQY logoHQYHealthEquity, Inc.7.6B33.123.38.5%
DODOCS logoDOCSDoximity, Inc.5.6B34.320.115.3%
WAWAY logoWAYWaystar Holding Corp.5.4B37.116.83.4%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/05 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue531,822693,3981,271,789
Gross Profit286,175381,113797,897
EBITDA-133,328-610,417-118,507
Operating Income-196,083-691,082-252,872
Net Income-214,118-705,809-245,028

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets564,052926,1162,274,838
Total Liabilities1,946,215869,7771,783,512
Total Stockholders Equity-1,382,16356,339491,326
Total Debt488,142468,094815,705
Cash and Cash Equivalents165,767340,954604,787

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-214,339-189,045-218,090
Capital Expenditure-34,608-22,1210
Free Cash Flow-248,947-211,166-218,090
Net Income-214,118-705,809-245,028
Net Change in Cash-137,124175,2280

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)3,158,404.733Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)3,373,956.596Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)3,253,215.967Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)778,603.471Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)833,328.985Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)802,673.961Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)482,908.201Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)526,141.357Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)501,923.888Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)2,343,188.391Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)2,503,104.129Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)2,413,527.882Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)2.880Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)3.020Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)2.770Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)12Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)4Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
693.398M  ?P/S
 (TTM)
: 
8.68
?Net Income
 (TTM)
: 
-705.809M  ?P/E
 (TTM)
: 
-49.6
?Enterprise Value
 (TTM)
: 
13.271B  ?EV/FCF
 (TTM)
: 
-48.62
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-54.7%  ?ROIC
 (TTM)
: 
-13.95%
?Net Debt
 (TTM)
: 
19.831M  ?Debt/Equity
 (TTM)
: 
3.25
?P/B
 (TTM)
: 
28.68  ?Current Ratio
 (TTM)
: 
3.3

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates TEM intrinsic value between $27.51 – $41.87 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate TEM Intrinsic Value

Common questions about TEM valuation

Is Tempus AI, Inc. (TEM) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Tempus AI, Inc. (TEM) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is TEM a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether TEM trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is TEM’s P/E ratio?

You can see TEM’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for TEM?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is TEM a good long-term investment?

Whether TEM fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Tempus AI, Inc.

  • Tempus AI, Inc. intrinsic value calculatorEstimate what the business is worth
  • Tempus AI, Inc. 5-year outlookWhat has to go right, and what could go wrong
TEM

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

2.12
MarketSnap

Trading Metrics:

Open: 65.1   Previous Close: 68.32
Day Low: 63.6   Day High: 70.63
Year Low: 40.77   Year High: 97.25
Price Avg 50: 66.96   Price Avg 200: 56.72
Volume: 4.289M   Average Volume: 6.804M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases
13-10-2026 06:00
Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases
Tempus AI Expands Strategic Collaborations to Drive Future Growth
12-10-2026 12:51
Tempus AI Expands Strategic Collaborations to Drive Future Growth
Tempus AI: Data And Applications Will Unlock More Upside
21-09-2026 23:37
Tempus AI: Data And Applications Will Unlock More Upside
Tempus AI Sees Pricing, Data Growth Fueling Long-Term Expansion
21-09-2026 20:02
Tempus AI Sees Pricing, Data Growth Fueling Long-Term Expansion
Tempus AI stock is soaring: does it have more upside to go?
18-09-2026 09:30
Tempus AI stock is soaring: does it have more upside to go?
Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
04-09-2026 09:00
Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze TEM →
    • FindStock Picks / Stock Screener
    • Value · TEMIntrinsic Value Calculator
    • Invest · TEMInvestment Case
    • Hold · TEM5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Settings
    • Public profile ↗
  • Log in

Media

Watch Listen Read